Noticias de REGN_US

Noticias del mercado

Últimas noticias sobre REGN_US — 150 novedades recientes. Análisis, balances, opiniones y cobertura de prensa.

Ticker: REGN_US ✕ 150 resultados
23/04/2026 REGN_US — Investing.com
Regeneron to offer gene therapy free, align U.S. drug prices globally
23/04/2026 REGN_US — GuruFocus
Regeneron Pharmaceuticals (REGN) Receives FDA Accelerated Approval for Otarmeni
23/04/2026 REGN_US — Pharmacy Times ES ← EN
La FDA concede aprobación acelerada a Otarmeni, la primera y única terapia genética para la pérdida auditiva genética
23/04/2026 REGN_US — The Manila Times
Regeneron Announces Agreement with U.S. Government to Help Lower Drug Costs for American Patients and Will Provide Innovative New Gene Therapy for Free in the U.S.
23/04/2026 REGN_US — Quiver Quantitative
Regeneron Announces Free Gene Therapy for U.S. Patients and New Price Alignment Strategies for Medications
23/04/2026 REGN_US — Stock Titan
A new gene therapy for rare hearing loss will be free in the U.S.
23/04/2026 REGN_US — Reuters
Regeneron to offer prescriptions at most favored nation prices, Trump says
23/04/2026 REGN_US — Fierce Pharma
Regeneron unveils latest 'most favored nation' drug pricing deal with White House
23/04/2026 REGN_US — GuruFocus
Regeneron (REGN) Receives FDA Approval for Innovative Gene Thera
23/04/2026 REGN_US — GuruFocus ES ← EN
REGN mantenido por TD Cowen - Precio objetivo elevado a $960
23/04/2026 REGN_US — GuruFocus
Regeneron Pharmaceuticals (REGN) Secures Pricing Deal with U.S. Government
23/04/2026 REGN_US — GuruFocus
Regeneron (REGN) Secures Agreement to Reduce Drug Prices Amid Ne
23/04/2026 REGN_US — The New York Times
New Gene Therapy Enables Children With a Rare Form of Deafness to Hear
23/04/2026 REGN_US — Stocktwits
Regeneron's Gene Therapy For Genetic Hearing Loss Gets Accelerated FDA Nod — Drug Pricing Deal With White House To Be Announced Today
23/04/2026 REGN_US — Intellectia AI ES ← EN
Regeneron recibe la aprobación de la FDA para la terapia génica Otarmeni
23/04/2026 REGN_US — Reuters
Regeneron wins FDA approval for first gene therapy for genetic hearing loss
23/04/2026 REGN_US — BioSpace
FDA approval of Regeneron’s hearing loss gene therapy breaks barriers
23/04/2026 REGN_US — Yahoo Finance ES ← EN
Dupixent de SNY y REGN obtiene la aprobación de la FDA para uso pediátrico en la urticaria
23/04/2026 REGN_US — Seeking Alpha
Regeneron wins FDA approval for hearing loss therapy
23/04/2026 REGN_US — MarketBeat
Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Raised to $960.00 at TD Cowen

Página 2 de 8

keyboard_arrow_up